PERK: A novel therapeutic target for neurodegenerative diseases?

33Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Identification of therapeutic targets based on novel mechanistic studies is urgently needed for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and prion disease. Multiple lines of evidence have emerged to suggest that inhibition of the stress-induced endoplasmic reticulum kinase PERK (protein kinase RNA-like endoplasmic reticulum kinase) is a potential therapeutic strategy for these diseases. A recently published study demonstrated that oral treatment with a newly characterized PERK inhibitor was able to rescue disease phenotypes displayed in prion disease model mice. Here, we discuss the background and rationale for targeting PERK as a viable therapeutic approach as well as implications of these findings for other neurodegenerative diseases. The promise and caveats of applying this strategy for disease therapy also are discussed. © 2014 Ma and Klann; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Ma, T., & Klann, E. (2014). PERK: A novel therapeutic target for neurodegenerative diseases? Alzheimer’s Research and Therapy, 6(3). https://doi.org/10.1186/alzrt260

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free